Despite prominent research demonstrating the potential of inhibiting the expression of c-Jun and c-FOS or blocking their related binding domain as therapeutic targets for cancers, no AP-1 family member inhibitor has been approved for practical clinical use [19]. Here, FOSB is linked to cancer.